First, to verify that FGFR3 mutations, rather than TP53 mutations, were associated with lower ITH in BLCA, we divided the 109 samples [24] into three groups: TP53-mutant, FGFR3-mutant, and no TP53 and FGFR3-mutant. The gene discussed is TP53; the disease is bladder transitional cell carcinoma.